PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives

Geburtshilfe und Frauenheilkunde

Volumn 76, Issue 2, 2016, Pages 164-169

  Sehouli, J ^a   Braicu, E I ^a   Chekerov, R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

BRCA; molecular pathway; ovarian cancer; PARP inhibitors

Indexed keywords

A 7016; ANGIOGENESIS INHIBITOR; AZD 2461; CEP 9722; E 7449; INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RUCAPARIB; TALAZOPARIB; UNCLASSIFIED DRUG; VELIPARIB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; DNA REPAIR; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

EID: 84959537342     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0035-1558185     Document Type: Article

References (40)

1. Robert Koch-Institut Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., Hrsg Krebs in Deutschland 2009/2010. 9. Ausgabe. Berlin: 2013
2. Marchetti C., Imperiale L., Gasparri M. L. et al. Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opin Investig Drugs: 2012; 21 1575 1584
3. Antoniou A., Pharoah P. D., Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet: 2003; 72 1117 1130
4. Bolton K. L., Chenevix-Trench G., Goh C. et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA: 2012; 307 382 390
5. The Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature: 2011; 474 609 615
6. Ledermann J., Harter P., Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol: 2014; 15 852 861
7. Rouleau M., Patel A., Hendzel M. J. et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer: 2010; 10 293 301
8. Do K., Cehn A. P. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res: 2012; 19 977 984
9. Lord C. J., Ashworth A. The DNA damage response and cancer therapy. Nature: 2012; 481 287 294
10. Patel A. G., Sarkaria J. N., Kaufmann S. H. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A: 2011; 108 3406 3411
11. Murai J., Huang S. Y., Das B. B. et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res: 2012; 72 5588 5599
12. Mateo J., Ong M., Tan D. S. et al. Appraising iniparib, the PARP inhibitor that never was-what must we learn? Nat Rev Clin Oncol: 2013; 10 688 696
13. Fong P. C., Yap T. A., Boss D. S. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol: 2010; 28 2512 2519
14. Audeh M. W., Carmichael J., Penson R. T. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet: 2010; 376 245 251
15. Gelmon K. A., Tischkowitz M., Mackay H. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol: 2011; 12 852 861
16. Kaye S. B., Lubinski J., Matulonis U. et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol: 2012; 30 372 379
17. Ledermann J., Harter P., Gourley C. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med: 2012; 366 1382 1392
18. Fong P. C., Boss D. S., Yap T. A. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med: 2009; 361 123 134
19. Kummar S., Kinders R., Gutierrez M. E. et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol: 2009; 27 2705 2711
20. Kummar S., Ji J., Morgan R. et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res: 2012; 18 1726 1734
21. EMCC Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant. Oncology (Williston Park): 2011; 25 1213 1232
22. Kummar S., Chen A., Ji J. et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res: 2011; 71 5626 5634
23. Coleman R. L., Sill M., Aghajanian C. et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation. SGO Annual Meeting. Abstr. 136; presented March 25, 2014.
24. Jones P., Altamura S., Boueres J. et al. Discovery of 2-{4-[(3 S)-piperidin-3-yl]phenyl}-2 H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem: 2009; 52 7170 7185
25. Sandhu S. K., Schelman W. R., Wilding G. et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol: 2014; 14 882 892
26. Ihnen M., zu Eulenburg C., Kolarova T. et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther: 2013; 12 1002 1015
27. Kristeleit R. S., Shapiro G., LoRusso P. et al. A phase I dose escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors. J Clin Oncol: 2013; 31 (Suppl.) Abstr. 2585
28. Kristeleit R. S., Burris H. A., LoRusso P. et al. Phase 1/2 study of oral rucaparib: final phase 1 results. J Clin Oncol: 2014; 32 (Suppl.) Abstr. 2573
29. Shen Y., Rehman F. L., Feng Y. et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res: 2013; 19 5003 5015
30. DeBono J. S., Mina L. A., Gonzalez M. et al. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. J Clin Oncol: 2013; 31 (Suppl.) Abstr. 2580
31. Reinbolt R. E., Hays J. L. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol: 2013; 3 237
32. Oza A. M., Cibula D., Oaknin A. et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. J Clin Oncol: 2012; 30 (Suppl.) Abstr. 5001
33. Juvekar A., Burga L. N., Hu H. et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov: 2012; 2 1048 1063
34. Bindra R. S., Schaffer P. J., Meng A. et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol: 2004; 24 8504 8518
35. Bindra R. S., Gibson S. L., Meng A. et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res: 2005; 65 11597 11604
36. Chan N., Pires I. M., Bencokova Z. et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res: 2010; 70 8045 8054
37. Dean E., Middleton M. R., Pwint T. et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer: 2012; 106 468 474
38. Liu J. F., Tolaney S. M., Birrer M. et al. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer: 2013; 49 2972 2978
39. Liu J. F., Barry W. T., Birrer M. et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol: 2014; 15 1207 1214
40. Liu J. F., Barry W. T., Birrer M. et al. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. ASCO Annual Meeting. Abstr. LBA5500; presented May 31, 2014.